GlassScriptPhysician profile
Monique Germain
NPI 1366947418
$2,462.87
in general payments reported to CMS, 2019-2025
25 companies · $932 in 2025
The $932 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $408 · 2023: $310 · 2024: $813 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.82 |
| Education | $298.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $590.27 | 2022-2025 | Enhertu, Imfinzi, Lynparza |
| Astellas Pharma US INC | $346.13 | 2024-2025 | Padcev |
| Incyte Corporation | $177.42 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $142.10 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Alexion Pharmaceuticals, INC. | $140.32 | 2022-2023 | Ultomiris |
| Daiichi Sankyo INC. | $125.93 | 2024-2025 | Enhertu, Injectafer |
| Sobi, INC | $125.25 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $112.44 | 2023 | Defitelio |
| Genzyme Corporation | $99.99 | 2022 | |
| Springworks Therapeutics, INC. | $91.29 | 2024-2025 | Ogsiveo |
| Regeneron Healthcare Solutions, INC. | $73.66 | 2023-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $65.20 | 2022-2025 | Iclusig, Fruzaqla |
| Array Biopharma INC | $57.63 | 2025 | Braftovi, Mektovi, Tukysa |
| Puma Biotechnology, INC. | $45.26 | 2025 | |
| Abbvie INC. | $31.84 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $30.66 | 2024-2025 | Verzenio, Jaypirca |
| Kite Pharma, INC. | $28.63 | 2025 | Yescarta |
| Genmab U.S., INC. | $25.27 | 2025 | Epkinly |
| Adaptive Biotechnologies Corporation | $23.33 | 2025 | Clonoseq |
| Legend Biotech USA INC. | $23.27 | 2025 | Carvykti |
| Merck Sharp & Dohme LLC | $22.39 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $22.31 | 2025 | Onivyde |
| Eisai INC. | $21.87 | 2025 | |
| Stemline Therapeutics INC. | $20.75 | 2025 | Orserdu |
| Blueprint Medicines Corporation | $19.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Germain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.